Open access
Oct 2026
Delayed eosinophilic fasciitis following adjuvant pembrolizumab for renal cell carcinoma: a case report
Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in various malignancies, including renal cell carcinoma (RCC). Pembrolizumab, an anti-PD-1 monoclonal antibody, is an established adjuvant therapy for high-risk localized RCC. However, ICIs are associated with a unique spectrum of i...
Kassem Salam, Sara El Meski, Mohamad Mourad et al.
· Journal of Medical Case Repo... · 0 citations